Press Release Dec 31 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
The drug has completed a pivotal Phase III clinical trial and has applications pending with regulatory authorities in multiple regions. Wockhardt's ongoing commitment to antibiotic innovation is highlighted by its extensive drug discovery portfolio targeting resistant infections.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Wockhardt
- Press Release Dec 01 2025
- Press Release Nov 03 2025
- Press Release Oct 01 2025
- Press Release Sep 25 2025
- Press Release Aug 08 2025
Later from Wockhardt
- Wockhardt Limited Press Release Jan 07 2026
- Wockhardt Limited Press Release Jan 27 2026
- Press Release Feb 10 2026
- Wockhardt Limited Press Release Mar 30 2026
- Press Release May 04 2026
Follow Wockhardt into a list and get an email when it puts out news.
Follow Wockhardt